Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

• Published in: Blood Vol. 108; no. 7; pp. 2244 - 2247
• Main Authors: Hulot, Jean-Sébastien, Bura, Alessandra, Villard, Eric, Azizi, Michel, Remones, Véronique, Goyenvalle, Catherine, Aiach, Martine, Lechat, Philippe, Gaussem, Pascale
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.10.2006; The Americain Society of Hematology
• Subjects: Adolescent; Adult; Alleles; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - physiology; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Homozygote; Humans; Male; Medical sciences; Mixed Function Oxygenases - genetics; Mixed Function Oxygenases - physiology; Pharmacogenetics; Pharmacology. Drug treatments; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Function Tests; Polymorphism, Genetic; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology; Human; Pharmacogenetics; Genetic variability; Healthy subject; Enzyme; Cytochrome P450; Genetics; Clopidogrel; Genotype; Thienopyridine derivative; Antiplatelet agent; Polymorphism

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubject variability. To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F,...